Literature DB >> 22187981

Enhancing factor VIII and VIIIa stability by combining mutations at the A2 domain interface and A1-C2 domain interface.

H Wakabayashi, A E Griffiths, P J Fay.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22187981      PMCID： PMC3291809          DOI： 10.1111/j.1538-7836.2011.04597.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  9 in total

Review 1.  Activation of factor VIII and mechanisms of cofactor action.

Authors:  Philip J Fay
Journal:  Blood Rev       Date:  2004-03       Impact factor: 8.250

Review 2.  Mutating factor VIII: lessons from structure to function.

Authors:  Philip J Fay; P Vincent Jenkins
Journal:  Blood Rev       Date:  2005-01       Impact factor: 8.250

3.  Identification of residues contributing to A2 domain-dependent structural stability in factor VIII and factor VIIIa.

Authors:  Hironao Wakabayashi; Philip J Fay
Journal:  J Biol Chem       Date:  2008-02-25       Impact factor: 5.157

4.  Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex.

Authors:  Jacky Chi Ki Ngo; Mingdong Huang; David A Roth; Barbara C Furie; Bruce Furie
Journal:  Structure       Date:  2008-04       Impact factor: 5.006

5.  Increasing hydrophobicity or disulfide bridging at the factor VIII A1 and C2 domain interface enhances procofactor stability.

Authors:  Hironao Wakabayashi; Amy E Griffiths; Philip J Fay
Journal:  J Biol Chem       Date:  2011-05-31       Impact factor: 5.157

6.  pH-dependent denaturation of thrombin-activated porcine factor VIII.

Authors:  P Lollar; C G Parker
Journal:  J Biol Chem       Date:  1990-01-25       Impact factor: 5.157

7.  Human factor VIIIa subunit structure. Reconstruction of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit.

Authors:  P J Fay; P J Haidaris; T M Smudzin
Journal:  J Biol Chem       Date:  1991-05-15       Impact factor: 5.157

8.  Generation of enhanced stability factor VIII variants by replacement of charged residues at the A2 domain interface.

Authors:  Hironao Wakabayashi; Fatbardha Varfaj; Jennifer Deangelis; Philip J Fay
Journal:  Blood       Date:  2008-07-23       Impact factor: 22.113

9.  Combining mutations of charged residues at the A2 domain interface enhances factor VIII stability over single point mutations.

Authors:  H Wakabayashi; A E Griffiths; P J Fay
Journal:  J Thromb Haemost       Date:  2008-12-04       Impact factor: 5.824
  9 in total
  3 in total

1.  Noncovalent stabilization of the factor VIII A2 domain enhances efficacy in hemophilia A mouse vascular injury models.

Authors:  Lilley Leong; Derek Sim; Chandra Patel; Katherine Tran; Perry Liu; Elena Ho; Thomas Thompson; Peter J Kretschmer; Hironao Wakabayashi; Philip J Fay; John E Murphy
Journal:  Blood       Date:  2014-10-20       Impact factor: 22.113

2.  Effects of replacement of factor VIII amino acids Asp519 and Glu665 with Val on plasma survival and efficacy in vivo.

Authors:  Matthew P Kosloski; Krithika A Shetty; Hironao Wakabayashi; Philip J Fay; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2014-06-17       Impact factor: 4.009

Review 3.  Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy.

Authors:  Benjamin J Samelson-Jones; Valder R Arruda
Journal:  Mol Ther Methods Clin Dev       Date:  2018-12-31       Impact factor: 6.698
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.